A Placebo-Controlled Trial of Bupropion Combined with Nicotine Patch for Smoking Cessation in Schizophrenia

BACKGROUND: Schizophrenics smoke at higher rates (58-88%) than the general population (~22%), and have great difficulty with quitting smoking. We determined if the combination of sustained-release (SR) bupropion (BUP) with transdermal nicotine patch (TNP) is well-tolerated, and superior to placebo (...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: George, Tony P., Vessicchio, Jennifer C., Sacco, Kristi A., Weinberger, Andrea H., Dudas, Melissa M., Allen, Taryn M., Creeden, Cerissa L., Potenza, Marc N., Feingold, Alan, Jatlow, Peter I.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2007
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2693008/
https://ncbi.nlm.nih.gov/pubmed/18096137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biopsych.2007.11.002
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak